title: Scintigraphy with J001 macrophage targeting glycolipopeptide. A new approach for sarcoidosis imaging.
abstract: Scintigraphy with radiolabeled J001 as a ligand for macrophage targeting is a new approach for sarcoidosis imaging. J001 is a fully characterized acylated peptido-poly (1,3) galactoside isolated from Klebsiella membrane proteoglycans and able to bind electively recruited macrophages. Its physiochemical properties allow rapid absorption by the respiratory tract when this agent, labeled by 99m technetium, is administered as an aerosol. Images are obtained within 3 to 5 h after inhalation. In the present study, we determined the ability of J001 scintigraphy to localize areas of sarcoidosis involvement in 22 patients compared with gallium scanning in ten of them. Nineteen patients underwent bronchoalveolar lavage (BAL) and serum angiotensin-converting enzyme (ACE) assay. J001 scintigraphy was also performed on a control group of six patients with extrathoracic melanoma, in whom J001 scintigraphy was used to evaluate the cutaneous extent of the tumor and the lymph node involvement. In this control group, no fixation appeared in the thoracic area. In the sarcoidosis group, 18 positive results were observed. One stage 0 patient had a mediastinal fixation. Five of the six stage 1 patients had a fixation located in the mediastinum, the lungs, and the wrists. Five of the six stage 2 patients had positive foci located in the mediastinum or the lung areas and in the myocardium in one of them. Six of the nine stage 3 patients had positive J001 scintigraphy occurring in the lungs and/or the mediastinum. One patient had a fixation on the main bronchi. J001 scintigraphy and gallium scanning, performed in ten patients, were positive in seven of them. There were discrepancies between the BAL results and J001 scintigraphy, as well as between the ACE results and J001 scintigraphy. In conclusion, 99mTc-J001 scintigraphy appears to be a sensitive and rapid technique for the imaging of thoracic sarcoidosis at the three stages of the disease.
authors.affiliation: Laboratoire de Biophysique Cellulaire, INSERM U316, Faculté de Médecine de Tours, France.
authors.forename: P
authors.initials: P
authors.lastname: Diot
authors.forename: E
authors.initials: E
authors.lastname: Lemarié
authors.forename: J L
authors.initials: JL
authors.lastname: Baulieu
authors.forename: S
authors.initials: S
authors.lastname: Pascal
authors.forename: L
authors.initials: L
authors.lastname: Vaillant
authors.forename: J P
authors.initials: JP
authors.lastname: Revillard
authors.forename: H
authors.initials: H
authors.lastname: Binz
authors.forename: G
authors.initials: G
authors.lastname: Normier
authors.forename: A
authors.initials: A
authors.lastname: Le Pape
mesh_terms: D000328:Adult; D000336:Aerosols; D001992:Bronchoalveolar Lavage Fluid; D005260:Female; D005697:Galactosides; D005710:Gallium Radioisotopes; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging*; D008171:Lung Diseases / Q000000981:diagnostic imaging*; D016676:Macrophages, Alveolar / Q000378:metabolism*; D008297:Male; D008477:Mediastinal Diseases / Q000000981:diagnostic imaging*; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D011869:Radioligand Assay; D011877:Radionuclide Imaging; D012507:Sarcoidosis / Q000000981:diagnostic imaging*; D013667:Technetium
chemical_list: D000336:Aerosols; D005697:Galactosides; D005710:Gallium Radioisotopes; D013667:Technetium; D007703:Peptidyl-Dipeptidase A